US President Donald Trump announced steep tariffs on imported generic medicines, effective from August 2028, with the aim of boosting domestic pharmaceutical production. This policy, which includes a phased increase in tariffs up to 200 per cent, could significantly impact India, a major global supplier of generic drugs to the US market.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
'Improved law and order and transparent governance have helped change UP's investment image.'
India's outward foreign direct investment (FDI) plummeted by 47.9 per cent year-on-year to $3 billion in June 2026, according to the Reserve Bank of India (RBI), with declines across equity, debt, and guarantee commitments.
Indian stock market benchmark indices, Sensex and Nifty, saw significant gains in early trade, driven by a sharp decline in crude oil prices and easing geopolitical tensions, alongside renewed foreign fund inflows.
Combine a robust base health plan with a super top-up, critical illness cover and a dedicated medical corpus to protect household finances from soaring treatment costs.
Indian benchmark indices, Sensex and Nifty, opened in positive territory, primarily driven by a strong performance in IT stocks, sustained foreign fund inflows, and a dip in global crude oil prices, despite a hawkish stance from the US Federal Reserve. Track Sensex, Nifty on July 30.
Indian benchmark stock indices, Sensex and Nifty, extended their winning streak to a fourth day, with Nifty surging 1.60 per cent, driven by a sharp decline in crude oil prices and renewed foreign fund inflows.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
Indian benchmark indices, Sensex and Nifty, opened higher on Friday, primarily driven by a significant surge in Bajaj Finance shares following its strong Q1 FY27 earnings report, coupled with continued foreign fund inflows and a dip in crude oil prices. Track Sensex, Nifty on July 31.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, driven by renewed tensions between the US and Iran and a subsequent spike in global crude oil prices, creating uncertainty in the market. Track Sensex, Nifty on July 8.
Indian benchmark equity indices closed higher on Thursday, with the Sensex gaining 273.55 points to 77,928.15 and the Nifty rising 66.95 points to 24,317.15, driven by bargain hunting and short-covering in IT and auto sectors.
Homegrown pharma major Cipla Ltd reported a 39 per cent decline in consolidated net profit to Rs 785.55 crore in the first quarter ended June 2026, primarily due to a dip in sales in the North American market and higher expenses.
India's pharmaceutical exports have shown robust growth, reaching over USD 28 billion, despite global economic challenges. The sector is projected to reach USD 130 billion by 2030.
Indian benchmark indices Sensex and Nifty rebounded in early trade on Thursday, recovering from a sharp fall in the previous session, driven by foreign fund inflows and buying in key blue-chip stocks. Track Sensex, Nifty on July 9, 2026.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, with the Sensex falling over 500 points and the Nifty over 150 points, as Brent crude oil prices surged past USD 100 per barrel due to escalating geopolitical tensions in the West Asia. track sensex, Nifty on July 24.
Congress MP from Jalandhar, Charanjit Singh Channi, was conspicuous by his absence when party leader Rahul Gandhi spoke in a debate in the Lok Sabha on Wednesday, bringing to the fore the recent rift within the party's state unit.
Indian benchmark indices Sensex and Nifty rallied in early trade, primarily driven by strong buying in IT stocks after Tech Mahindra reported a significant 28.4 per cent rise in its consolidated net profit for the June quarter.
Indian benchmark indices Sensex and Nifty experienced a downturn in early trade, primarily influenced by a dip in HDFC Bank shares, persistent outflows from foreign funds, and escalating geopolitical tensions between the US and Iran. Track Sensex, Nifty performance.
India's domestic pharmaceutical market recorded its highest value growth in five quarters during Q4 FY26, driven primarily by pricing and an early indication of volume recovery, with a significant structural shift towards chronic and sub-chronic therapies.
The Maharashtra Food and Drug Administration (FDA) conducted three separate operations in Pune and Kolhapur, seizing illegal medicines worth over Rs 24 lakh. Actions included seizing allopathic medicines from an unlicensed firm and prescription drugs with improper promotional packaging, with the FDA vowing strict action against violators.
Indian benchmark indices, Sensex and Nifty, experienced subdued trading and turned flat on Tuesday as investors engaged in profit-booking following a recent rally, compounded by weak Asian market trends and fresh foreign fund outflows.
Indian benchmark indices, Sensex and Nifty, experienced a significant downturn as escalating tensions in West Asia led to a sharp surge in crude oil prices, coupled with fresh foreign fund outflows and a weakening rupee.
Indian stock markets witnessed a significant rally, with the Sensex climbing 964.58 points and the Nifty reaching 24,330, driven by strong buying in blue-chip stocks, particularly in the IT and banking sectors, amidst optimism over Q1 earnings and a shift towards large-cap investments.
Dr Reddy's Laboratories reported a 68.7 per cent year-on-year decline in consolidated net profit to Rs 443.5 crore in Q1 FY27, primarily due to the end of its lenalidomide sales agreement, a Rs 240-crore provision for semaglutide API inventory quality issues, and elevated freight costs.
Indian benchmark indices Sensex and Nifty continued their upward trend for a second consecutive day, with the Sensex gaining over 800 points, driven by strong performances from heavyweights like Reliance Industries, ICICI Bank, and HDFC Bank, alongside positive cues from easing crude oil prices and robust IT sector earnings.
Delhi Police arrested three men involved in an illegal network supplying banned pharmaceutical drugs across Delhi and the NCR. The accused, working as medical representatives, were caught with substantial quantities of psychotropic substances and controlled medicines.
Indian benchmark indices Sensex and Nifty surged in early trade, with the Sensex jumping nearly 700 points, primarily driven by strong buying in IT stocks following TCS's positive June-quarter results and optimistic demand outlook. Track Sensex, Nifty on July 10, 2026.
Indian benchmark indices, Sensex and Nifty, staged a moderate rebound after a significant correction in the previous session, driven by foreign fund inflows and a largely positive trend in global markets, though geopolitical tensions between the US and Iran continued to foster caution.
Danish pharma major Novo Nordisk has launched 'Awiqli' in India, a once-weekly basal insulin injection for adults with diabetes, aiming to simplify treatment and reduce the burden of daily injections.
Indian benchmark equity indices, Sensex and Nifty, extended their winning streak for a third consecutive day, driven by a rally in IT stocks and global cues suggesting a more accommodative monetary policy after softer-than-expected US jobs data.
The launch highlights the growing maturity of India's nuclear medicine ecosystem.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
In a major development in the toxic syrup tragedy that killed 23 children in Madhya Pradesh, S Ranganathan, director of the Tamil Nadu-based Sresan Pharmaceuticals, has been arrested and remanded to 10 days' police custody.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
'Once the 60-plus population hits 20 to 30 per cent of the country, the demand for elderly-care treatments will surge -- cardiac, metabolic, neurological, and musculoskeletal medicines are going to dominate the market for the next several decades.'
Indian stock markets, including the Sensex and Nifty, rebounded significantly, driven by a decline in crude oil prices and positive global cues stemming from hopes of diplomatic progress in US-Iran negotiations.
Indian benchmark indices, Sensex and Nifty, experienced a significant drop of over 1 per cent, driven by a bearish trend in global markets, weakness in HDFC Bank and IT firms, and fresh foreign fund outflows.